Literature DB >> 14636301

Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment.

T A Miettinen1, H Gylling.   

Abstract

BACKGROUND: Serum contains noncholesterol sterols, which are reliable markers of cholesterol metabolism, but their presence and importance in different lipoproteins have been insufficiently studied.
MATERIALS AND METHODS: Serum and lipoprotein cholesterol precursors squalene, cholestanol, desmosterol and lathosterol (markers of cholesterol synthesis) and cholestanol and plant sterols (markers of cholesterol absorption), and absorption efficacy and absolute synthesis of cholesterol were studied at baseline and during 6-month atorvastatin (80 mg day(-1)) treatment by the sterol balance technique in men with type 2 diabetes.
RESULTS: At baseline, approximately 14% of serum squalene was transported by VLDL, 12% by IDL, 40% by LDL and 30% by HDL. The respective values for the noncholesterol sterols were approximately 8, 4, 61 and 26%. The squalene to cholesterol ratios were highest in VLDL and IDL, those of cholestanol, desmosterol and absorption marker sterols were gradually higher, and that of lathosterol lower from VLDL to HDL. Atorvastatin reduced LDL cholesterol by approximately 50%, decreased the absolute cholesterol synthesis and turnover by approximately 40%, but increased significantly the fractional and mass absorption of cholesterol. In accordance with the fecal data, the ratios of the precursor sterols to cholesterol were reduced (-50%), but those of squalene (+48%) and the absorption sterols increased (e.g. 2.6-fold for sitosterol) similarly in each lipoprotein, but progressively from VLDL to HDL.
CONCLUSIONS: Effective lowering of LDL cholesterol by large dose of statin is associated with decreased synthesis and turnover of cholesterol and increased fractional and mass absorption of cholesterol. These changes are detectable by noncholesterol sterols in serum and in different lipoprotein fractions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14636301     DOI: 10.1046/j.1365-2362.2003.01229.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  24 in total

1.  Metabolomic Endotype of Asthma.

Authors:  Suzy A A Comhair; Jonathan McDunn; Carole Bennett; Jade Fettig; Serpil C Erzurum; Satish C Kalhan
Journal:  J Immunol       Date:  2015-06-05       Impact factor: 5.422

2.  Statins increase hepatic cholesterol synthesis and stimulate fecal cholesterol elimination in mice.

Authors:  Marleen Schonewille; Jan Freark de Boer; Laura Mele; Henk Wolters; Vincent W Bloks; Justina C Wolters; Jan A Kuivenhoven; Uwe J F Tietge; Gemma Brufau; Albert K Groen
Journal:  J Lipid Res       Date:  2016-06-16       Impact factor: 5.922

3.  Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men.

Authors:  André J Tremblay; Benoît Lamarche; Valéry Lemelin; Lizbeth Hoos; Suzanne Benjannet; Nabil G Seidah; Harry R Davis; Patrick Couture
Journal:  J Lipid Res       Date:  2010-12-01       Impact factor: 5.922

4.  Effect of evolocumab on cholesterol synthesis and absorption.

Authors:  Matthew Peach; Ren Xu; Dan Fitzpatrick; Lisa Hamilton; Ransi Somaratne; Robert Scott; Scott M Wasserman; C Stephen Djedjos
Journal:  J Lipid Res       Date:  2016-10-05       Impact factor: 5.922

Review 5.  Revisiting Human Cholesterol Synthesis and Absorption: The Reciprocity Paradigm and its Key Regulators.

Authors:  Peter A S Alphonse; Peter J H Jones
Journal:  Lipids       Date:  2015-11-30       Impact factor: 1.880

6.  Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway.

Authors:  Thomas M van Himbergen; Seiko Otokozawa; Nirupa R Matthan; Ernst J Schaefer; Aaron Buchsbaum; Masumi Ai; Lambertus J H van Tits; Jacqueline de Graaf; Anton F H Stalenhoef
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-10-15       Impact factor: 8.311

7.  Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers.

Authors:  Thomas M van Himbergen; Nirupa R Matthan; Nancy A Resteghini; Seiko Otokozawa; Masumi Ai; Evan A Stein; Peter H Jones; Ernst J Schaefer
Journal:  J Lipid Res       Date:  2008-11-30       Impact factor: 5.922

8.  The effects of statins and sitosterols: benefit or not?

Authors:  Tatu A Miettinen; Helena Gylling
Journal:  Curr Atheroscler Rep       Date:  2009-01       Impact factor: 5.113

9.  Association between cholesterol synthesis/absorption markers and effects of cholesterol lowering by atorvastatin among patients with high risk of coronary heart disease.

Authors:  Yue Qi; Jing Liu; Changsheng Ma; Wei Wang; Xiaohui Liu; Miao Wang; Qiang Lv; Jiayi Sun; Jun Liu; Yan Li; Dong Zhao
Journal:  J Lipid Res       Date:  2013-08-20       Impact factor: 5.922

10.  Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly.

Authors:  Eliana Polisecki; Inga Peter; Jason S Simon; Robert A Hegele; Michele Robertson; Ian Ford; James Shepherd; Christopher Packard; J Wouter Jukema; Anton J M de Craen; Rudi G J Westendorp; Brendan M Buckley; Ernst J Schaefer
Journal:  J Lipid Res       Date:  2009-09-14       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.